Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Transient cerebral dysfunction secondary to high-dose methotrexate.

R W Walker, J C Allen, G Rosen

    Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
    |December 1, 1986
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Personal experience, posttraumatic symptomatology, and meaning in life during the first months of the COVID-19 pandemic.

    Current psychology (New Brunswick, N.J.)·2021
    Same author

    Tracking and Assessing Oil Spill Toxicity to Aquatic Organisms: A Novel Approach.

    Environmental toxicology and chemistry·2021
    Same author

    Evaluating the efficacy of DGT to quantify copper in stormwater at end-of-pipe.

    Chemosphere·2019
    Same author

    Public Response to Suicide News Reports as Reflected in Computerized Text Analysis of Online Reader Comments.

    Archives of suicide research : official journal of the International Academy for Suicide Research·2019
    Same author

    Response to anti-PD1 therapy with nivolumab in metastatic sarcomas.

    Clinical sarcoma research·2017
    Same author

    Palliative CT-Guided Cordotomy for Medically Intractable Pain in Patients with Cancer.

    AJNR. American journal of neuroradiology·2016

    High-dose methotrexate (HDMTX) can cause a temporary neurologic syndrome in cancer patients. This syndrome, characterized by varied neurological signs, is reversible and does not prevent continued HDMTX treatment.

    Area of Science:

    • Neuro-oncology
    • Clinical Neurology
    • Pharmacology

    Background:

    • High-dose methotrexate (HDMTX) is a critical chemotherapy agent used for various malignancies.
    • Understanding potential adverse effects of HDMTX is crucial for patient management and treatment adherence.

    Observation:

    • A transient acute neurologic syndrome was observed in 22 patients undergoing HDMTX therapy (8 to 9 g/m2).
    • The syndrome manifested approximately six days after the second or third weekly HDMTX treatment.
    • Neurologic signs included behavioral changes, focal sensorimotor deficits, and abnormal reflexes, often with alternating lateralization.

    Findings:

    • Standard diagnostic evaluations such as CT scans, lumbar punctures, hemograms, and blood chemistry panels were unremarkable.
    • Electroencephalogram (EEG) results consistently showed some degree of slowing in affected patients.

    Related Experiment Videos

  • The etiology of this transient neurologic syndrome remains undetermined.

    • Implications:

    • The observed syndrome is typically transient, self-limiting, and does not usually recur.
    • The occurrence of this neurologic syndrome does not contraindicate further HDMTX treatment.
    • This highlights the importance of monitoring for specific neurologic toxicities associated with HDMTX chemotherapy.